Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production
Anja Brehm, … , Ivona Aksentijevich, Raphaela Goldbach-Mansky
Anja Brehm, … , Ivona Aksentijevich, Raphaela Goldbach-Mansky
Published October 20, 2015
Citation Information: J Clin Invest. 2015;125(11):4196-4211. https://doi.org/10.1172/JCI81260.
View: Text | PDF | Erratum
Research Article Immunology

Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production

  • Text
  • PDF
Abstract

Autosomal recessive mutations in proteasome subunit β 8 (PSMB8), which encodes the inducible proteasome subunit β5i, cause the immune-dysregulatory disease chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), which is classified as a proteasome-associated autoinflammatory syndrome (PRAAS). Here, we identified 8 mutations in 4 proteasome genes, PSMA3 (encodes α7), PSMB4 (encodes β7), PSMB9 (encodes β1i), and proteasome maturation protein (POMP), that have not been previously associated with disease and 1 mutation in PSMB8 that has not been previously reported. One patient was compound heterozygous for PSMB4 mutations, 6 patients from 4 families were heterozygous for a missense mutation in 1 inducible proteasome subunit and a mutation in a constitutive proteasome subunit, and 1 patient was heterozygous for a POMP mutation, thus establishing a digenic and autosomal dominant inheritance pattern of PRAAS. Function evaluation revealed that these mutations variably affect transcription, protein expression, protein folding, proteasome assembly, and, ultimately, proteasome activity. Moreover, defects in proteasome formation and function were recapitulated by siRNA-mediated knockdown of the respective subunits in primary fibroblasts from healthy individuals. Patient-isolated hematopoietic and nonhematopoietic cells exhibited a strong IFN gene-expression signature, irrespective of genotype. Additionally, chemical proteasome inhibition or progressive depletion of proteasome subunit gene transcription with siRNA induced transcription of type I IFN genes in healthy control cells. Our results provide further insight into CANDLE genetics and link global proteasome dysfunction to increased type I IFN production.

Authors

Anja Brehm, Yin Liu, Afzal Sheikh, Bernadette Marrero, Ebun Omoyinmi, Qing Zhou, Gina Montealegre, Angelique Biancotto, Adam Reinhardt, Adriana Almeida de Jesus, Martin Pelletier, Wanxia L. Tsai, Elaine F. Remmers, Lela Kardava, Suvimol Hill, Hanna Kim, Helen J. Lachmann, Andre Megarbane, Jae Jin Chae, Jilian Brady, Rhina D. Castillo, Diane Brown, Angel Vera Casano, Ling Gao, Dawn Chapelle, Yan Huang, Deborah Stone, Yongqing Chen, Franziska Sotzny, Chyi-Chia Richard Lee, Daniel L. Kastner, Antonio Torrelo, Abraham Zlotogorski, Susan Moir, Massimo Gadina, Phil McCoy, Robert Wesley, Kristina I. Rother, Peter W. Hildebrand, Paul Brogan, Elke Krüger, Ivona Aksentijevich, Raphaela Goldbach-Mansky

×

Figure 4

Proteasomal activity of PBMCs.

Options: View larger image (or click on image) Download as PowerPoint
Proteasomal activity of PBMCs.
(A) Proteasome activity of PBMCs from CAN...
(A) Proteasome activity of PBMCs from CANDLE/PRAAS patients (turquoise, Pt.1; orange, Pt.2; purple, Pt.4 and Pt.5; red, CANDLE patients with PSMB8 mutations), patient family members or heterozygous carriers (gray), healthy controls (HC, black), patients with an undifferentiated interferonopathy disease who are negative for proteasome gene mutations (UID, green), and active pretreatment NOMID patients (blue) was analyzed and expressed as percentage relative to the average of healthy controls. The dashed lines indicate 100% activity. Whole blood RNA samples from the same date for patient and patient family members were analyzed by qRT-PCR for IFN-regulated gene expression and an IFN score was calculated. For patient 2, we used control samples from nonrelated heterozygous carriers for the PSMB8 T75M (HZMa, HZMb, and HZMc) for comparison. Measurements for patient 4, patient 5, and their parents were performed at only 1 time point before treatment. Patients with PSMB8 mutations, C1 (T75M/T75M), C2 (C135X/C135X), and C3 (T75M/A92T), were assessed as CANDLE controls. Two-sample, 2-tailed t tests were performed, and P values were stated. Error bars indicate technical triplicates. (B) Patient proteasome activity was normalized to the UID mean for each of the proteasome activities. Paired t test was performed. (C) PBMCs from 3 healthy donors were stimulated with the indicated cytokines or none for 6, 12, or 24 hours. The cell numbers were counted and a proteasome activity assay was done. Fold changes of activity against no-treatment control was calculated. The dashed lines on the graph indicate the activity of no-treatment controls. The numbers on top of the data points are IFN scores. Data represent mean ± SEM from n = 3 samples. Two-sample, 2-tailed t tests were performed. *P < 0.05.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts